Analysts Set STAAR Surgical (NASDAQ:STAA) Target Price at $45.57

STAAR Surgical (NASDAQ:STAA) has received a consensus rating of “Hold” from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $45.57.

Several brokerages have weighed in on STAA. BTIG Research boosted their price target on STAAR Surgical from $46.00 to $53.00 and gave the company a “buy” rating in a report on Monday, July 15th. Stifel Nicolaus dropped their target price on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, August 26th. Morgan Stanley downgraded STAAR Surgical from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $50.00 to $37.00 in a research report on Monday, July 15th. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a report on Thursday, September 19th. Finally, Canaccord Genuity Group dropped their price objective on shares of STAAR Surgical from $43.00 to $41.00 and set a “hold” rating for the company in a research note on Thursday, August 8th.

Insiders Place Their Bets

In other news, Director Arthur C. Butcher acquired 1,315 shares of STAAR Surgical stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $37.99 per share, with a total value of $49,956.85. Following the purchase, the director now directly owns 4,208 shares of the company’s stock, valued at approximately $159,861.92. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On STAAR Surgical

Several large investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in STAAR Surgical by 313.9% during the 1st quarter. GAMMA Investing LLC now owns 1,308 shares of the medical instruments supplier’s stock worth $50,000 after purchasing an additional 992 shares during the period. Covestor Ltd raised its position in STAAR Surgical by 38.9% in the first quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock valued at $103,000 after purchasing an additional 754 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of STAAR Surgical during the second quarter worth about $129,000. Larson Financial Group LLC purchased a new stake in shares of STAAR Surgical in the second quarter worth about $130,000. Finally, nVerses Capital LLC grew its stake in shares of STAAR Surgical by 78.3% in the third quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier’s stock valued at $152,000 after buying an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Trading Up 0.2 %

Shares of STAA stock opened at $30.39 on Wednesday. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of 98.03 and a beta of 0.59. The firm has a 50-day moving average price of $32.45 and a 200 day moving average price of $39.28. STAAR Surgical has a twelve month low of $26.66 and a twelve month high of $52.68.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.09). The firm had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $95.22 million. STAAR Surgical had a return on equity of 5.60% and a net margin of 4.99%. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.23 earnings per share. As a group, research analysts predict that STAAR Surgical will post 0.16 earnings per share for the current year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.